story of the week
Temozolomide vs Temozolomide Plus Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
J. Clin. Oncol 2022 Oct 19;[EPub Ahead of Print], PL Kunz, NT Graham, PJ Catalano, HS Nimeiri, GA Fisher, TA Longacre, CJ Suarez, BA Martin, JC Yao, MH Kulke, AE Hendifar, JC Shanks, MH Shah, MM Zalupski, EL Schmulbach, DL Reidy-Lagunes, JR Strosberg, PJ O'Dwyer, AB BensonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.